## Edgar Filing: Evoke Pharma Inc - Form 4

Evoke Pharma In	c										
Form 4											
April 24, 2015								OMB A	PPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OND	3235-0287		
Check this box Washington, D.C. 20549							Number:	January 31,			
if no longer	MENT O	F CHAN	NGES IN	BENEF	Expires:	2005					
subject to Section 16.			SECUI	RITIES	Estimated burden ho						
Form 4 or Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Section 17	(a) of the	Public U	Jtility Hol	ding Cor		nge Act of 1934, t of 1935 or Sectio 1940	response	•		
(Print or Type Respon	nses)										
1. Name and Address of Reporting Person <u>*</u> Brady Todd C			2. Issuer Name <b>and</b> Ticker or Trading Symbol Evoke Pharma Inc [EVOK]				5. Relationship of Reporting Person(s) to Issuer				
(Last)	Middle)			_	(Chec			k all applicable)			
(Last) (First) (Middle)			3. Date of Earliest Transaction (Month/Day/Year)				X Director 10% Owner				
C/O EVOKE PH LOMAS SANTA SUITE 270			04/22/2	2015			Officer (giv below)	e title Oth below)	her (specify		
(Street)			4. If Amendment, Date Original			1	6. Individual or Joint/Group Filing(Check				
SOLANA BEAG	CH, CA 920	75	Filed(Mo	onth/Day/Yea	ır)		Applicable Line) _X_ Form filed by Form filed by Person	One Reporting P More than One R			
(City) (	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	ally Owned		
	ansaction Date th/Day/Year)	Execution any	Date, if	Code (Instr. 8)		(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V		(D) Price					
Reminder: Report on	a separate line	e for each cl	lass of sec	urities bene	-	-	or indirectly. spond to the colle	ction of	SEC 1474		
					inforn requii	nation con red to resp ays a curre	tained in this form ond unless the for ontly valid OMB co	are not m	(9-02)		
	Tab					posed of, or convertible	Beneficially Owned securities)	l			
1. Title of 2.	3. Trans	saction Date	e 3A. Dee	emed	4.	5. Numbe	r 6. Date Exercisa	ble and 7	. Title and Amount of 8.		

Derivative Conversion (Month/Day/Year) Execution Date, if Transaction Derivative Expiration Date

Underlying Securities De

## Edgar Filing: Evoke Pharma Inc - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	8)	Securities (Month/Day/Y) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Year)			Sec (In	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 6.43	04/22/2015		А		9,000		<u>(1)</u>	04/21/2025	Common Stock	9,000	
Reporting Owners												
	Donorting O	on Nomo / Adduss	-	R	elat	tionships	5					

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Brady Todd C C/O EVOKE PHARMA, INC. 505 LOMAS SANTA FE DRIVE, SUITE 270 SOLANA BEACH, CA 92075	Х			
Signatures				
/s/ Matthew J. D'Onofrio, Attorney-in-fact for T Brady	odd C.	04	/24/2015	5
<b>**</b> Signature of Reporting Person			Date	

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant (4/22/2016), subject to the reporting person's continued service to the Issuer through such vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.